%0 Journal Article
%T 原发CD5阳性弥漫大B细胞淋巴瘤一例并文献复习<br>The Primary CD5 Positive Diffuse Large B-Cell Lymphoma: A Case Report and Literature Review
%A 刘鹏
%A 许玥
%A 王彦丽
%A 李丽
%A 接贵涛
%J Advances in Clinical Medicine
%P 5803-5808
%@ 2161-8720
%D 2021
%I Hans Publishing
%R 10.12677/ACM.2021.1112858
%X 目的：探讨CD5阳性弥漫大B细胞淋巴瘤(DLBCL)的临床特点及治疗方案，提高对该病的认识。方法：回顾性分析临沂市中心医院2020年5月收治的1例CD5 (+) DLBCL患者资料，并结合相关文献进行讨论。结果：该患者相较于CD5 (？) DLBCL恶性程度更高，在接受R-CHOP方案、R-GDP方案以及泽布替尼 + BR方案治疗后，仍预后不良。结论：CD5 (+) DLBCL较少见，具有独特的临床特点，治疗反应差，在临床中我们应重视CD5在DLBCL中的表达。<br />
Objective: To explore the clinical characteristics and treatment options of CD5-positive diffuse large B-cell lymphoma (DLBCL) and to raise awareness of the disease. Methods: Retrospective analysis of the data of 1 CD5 (+) DLBCL patient admitted to Linyi Center Hospital in May 2020, and discussion in conjunction with relevant literature. Results: The patient had a higher malignancy degree than CD5 (？) DLBCL and still had poor prognosis after receiving treatment from R-CHOP, R-GDP, and Zanubrutinib + BR. Conclusion: CD5 (+) DLBCL is rare and has unique clinical characteristics, poor treatment response, in clinic, we should pay attention to CD5 expression in DLBCL.
%K 弥漫大B细胞淋巴瘤，CD5，临床特点，治疗，预后<br>Diffuse Large B-Cell Lymphoma
%K CD5
%K Clinical Features
%K Therapy
%K Prognosis
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=47326